Malaria is still one of the most deadly diseases in developing countries
Article
Today is World Malaria Day. Malaria is preventable and curable, yet it is still one of the most deadly diseases in developing countries. Despite extraordinary progress in the fight against malaria over the last 15 years, the disease still claims the life of a child every two minutes.
The Novartis Institute for Tropical Diseases convenes parasitology experts in Zambia
Article
On April 4-8 2016, the Novartis Institute for Tropical Diseases (NITD) held a Symposium on Parasitology in Lusaka, Zambia, bringing together international and local experts in the field with the aim of engaging in productive scientific exchange on parasitic diseases - including malaria, sleeping sickness (Human African Trypanosomiasis), Chagas, leishmaniasis, and cryptosporidiosis.
Novartis will provide medicines for high blood pressure and diabetes
Article
Syrian refugees in Lebanon suffering from chronic diseases face difficulties accessing diagnosis, medicines and ongoing care. The International Committee of the Red Cross (ICRC) and Novartis are partnering to improve care and treatment for the most vulnerable population in Lebanon. The objective is to establish a blueprint for improving diagnosis, treatment and follow-up for refugees, as well as members of their Lebanese host families, who suffer from chronic diseases.
Shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer
Article
We are pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular diseases, diabetes, respiratory conditions and breast cancer. The medicines are currently stored in the MEDS warehouse (Mission for Essential Drugs and Supplies) in Nairobi. MEDS is a faith-based not-for-profit medical supply chain and capacity building organization in Kenya.
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthcare industry. In addition, the publication of the CR report now coincides with the Novartis Annual Report, providing a more integrated view on the company’s performance.
Global Health and hypertension community gather to highlight innovative delivery models for hypertension management in low- and middle-income countries
Experts at London-based dialogue event will also focus on potential enablers to scale healthcare delivery models and critical need for evidence generation
Deaths from hypertension are estimated at 9.4 million people annually globally, which is equivalent to all infectious diseases combined
On May 25, Novartis Access held its second stakeholder dialogue in conjunction with the 2016 World Health Assembly to share first learnings from the Kenya launch, and to continue the discussion on how to address the burden of noncommunicable diseases (NCDs) in lower-income countries. This event is part of the company’s public commitment to transparency and open dialogue with stakeholders as Novartis Access is rolled out.
Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country
Summary:
• Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries • Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1 • Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs
Press Release
• Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries • Program supports Kenyan government on non-communicable disease (NCD) prevention and control – by 2030, NCDs are expected to cause more than 60% of deaths in the country1 • Agreements signed with Kenyan government and NGOs include programs to distribute medicines, raise disease awareness and strengthen healthcare system capabilities in key NCDs
